Kite Pharma (KITE) Tops Q3 EPS by 26c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/11/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. TMUS
7. SPY
8. CVS
9. UNH
10. AXP

Go back to Kite Pharma (KITE) Tops Q3 EPS by 26c

Kite Pharma Reports Third Quarter 2015 Financial Results and Provides Business Update

November 12, 2015 4:01 PM EST

SANTA MONICA, Calif., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq: KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT) products for the treatment of cancer, today reported financial results for the quarter ended September 30, 2015.

"Over the past few months, we have achieved many significant corporate and clinical development milestones, including the initiation of two pivotal Phase 2 studies of our lead product candidate, KTE-C19," noted Arie Belldegrun, M.D., FACS, Chairman, President, and Chief Executive Officer. "Our ZUMA-1 trial is enrolling patients with aggressive, refractory non-Hodgkin's lymphoma,... More